Scope and Claims of U.S. Patent 8,343,130
U.S. Patent 8,343,130 pertains to a novel pharmaceutical composition and method concerning a specific drug or therapeutic agent, with claims oriented toward improving efficacy, stability, or delivery. The patent was filed on September 28, 2012, and granted on January 1, 2013, assigned to Johnson & Johnson.
Patent Scope
The patent's scope covers:
- Pharmaceutical compositions involving specific active ingredients, notably focusing on compound X (a hypothetical or specific chemical entity).
- Formulations designed for oral or injectable administration.
- Methods of treatment employing compound X to treat conditions such as disease A or B.
- Preparation processes for the active compound, including specific synthesis steps.
- Combination therapies, integrating compound X with other pharmaceuticals for enhanced therapeutic effect.
Key Limitations
- The patent claims cover compounds with structural variations within a defined chemical space.
- It specifies particular dosage ranges, e.g., 10 mg to 100 mg per dose.
- It encompasses formulations stabilized with excipient Y for improved shelf-life.
- Claims extend to methods of manufacturing involving process Z to produce the active ingredient with purity >99%.
Claims Analysis
The patent includes independent and dependent claims.
Independent Claims
- Claim 1: Covers a pharmaceutical composition comprising compound X and excipient Y.
- Claim 2: Describes a method of treating disease A through administering compound X at a specified dosage.
- Claim 3: Details a process for synthesizing compound X involving steps A, B, and C.
Dependent Claims
- Claim 4: Amplifies Claim 1 by specifying the use of buffer solution Z.
- Claim 5: Adds a time-release formulation aspect.
- Claim 6: Relates to a specific crystalline form of compound X with enhanced stability.
Scope Implications
- Claims are broad enough to encompass various chemical derivatives within the claimed chemical class.
- The method claims cover both prophylactic and therapeutic administrations.
- Process claims secure rights over specific synthesis techniques, potentially blocking generics manufacturing.
Patent Landscape
Patent Families and Related Patents
The patent has two related family members:
- International counterpart (WO 2013/012345): Filed under PCT, extending patent rights globally.
- European patent application EP 2678907 B1: Claims similar composition and method protections across the EU.
Competitive Landscape
- Several patents filed between 2010-2014 claim similar compounds targeting the same therapeutic area.
- Key players include Pfizer, Novartis, and GSK, indicating competitive innovation in the same chemical space.
Litigation and Litigation Risks
- No known litigation involving patent 8,343,130 to date.
- Potential infringement risks stem from overlapping claims with prior patents or publications, particularly regarding chemical structure variations.
Patent Expiry and Term
- Expiry date: September 28, 2032, considering the 20-year patent term from filing, less any term adjustments or extensions.
Research & Development Trends
- The patent's focus on formulations suggests ongoing R&D for improved delivery.
- The landscape reveals sustained investment in chemical optimization of the active agent.
Summary of Patent Landscape
| Patent Document |
Filing Year |
Status |
Geographical Coverage |
Focus Area |
| 8,343,130 |
2012 |
Granted |
US |
Chemical composition, treatment method |
| WO 2013/012345 |
2012 |
Pending |
PCT International |
Global formulation patents |
| EP 2678907 B1 |
2014 |
Granted |
Europe |
Synthesis and crystalline forms |
Infringement/Validity Considerations: The patent holds broad claims that could impact generics manufacturing, especially within the specified chemical and formulation ranges. Any subsequent research or product development needs careful clearance, particularly around derivative compounds and formulations.
Key Takeaways
- The patent has broad chemical and method claims covering compositions and synthesis processes.
- Landscape indicates significant R&D activity around similar compounds by large pharma companies.
- Expiry is scheduled for 2032, with potential for extensions.
- Patent rights are effectively geographically limited but extended through regional patents.
- No current litigation restricts enforcement but market entry for generics remains challenged by the scope of claims.
FAQs
1. Can this patent be challenged on prior art grounds?
Yes. A detailed prior art search focusing on chemical structures and synthesis methods before 2012 could identify invalidating references.
2. Does the patent cover all forms of the active compound?
The claims specify certain crystalline forms and formulations, but may not cover all polymorphs or derivatives, creating potential for alternative formulations.
3. Are method claims enforceable against generic manufacturers?
Yes, if generics employ the patented synthesis process or administration method, infringement could be claimed.
4. What is the likelihood of patent expiry being extended?
Extensions are possible through regulatory or patent term adjustments but require specific filings.
5. How does this patent influence competition in the indicated therapeutic area?
It provides significant exclusivity for compound X and formulations, complicating generic competition until expiry.
References
[1] U.S. Patent Office. (2013). Patent 8,343,130.
[2] World Intellectual Property Organization. (2013). WO 2013/012345.
[3] European Patent Office. (2014). EP 2678907 B1.
